California GLP-1 Compounding Rules: A 2026 Compliance Guide for Providers

California's Board of Pharmacy and Medical Board enforce some of the strictest compounding rules in the country. For med spas, nurse practitioners, and prescribers operating in California, staying compliant with GLP-1 compounding regulations requires understanding a layered set of state and federal rules that have evolved significantly in 2025–2026.

California GLP-1 compounding sits at the intersection of three regulatory bodies:

California Board of Pharmacy: Regulates compounding pharmacies operating in California. Enforces USP standards, patient-specific prescription requirements, and state-specific compounding rules.

California Medical Board: Regulates physician prescribing practices. Has authority over prescribers who order compounded GLP-1s.

FDA: Federal oversight of compounding pharmacies, particularly 503B outsourcing facilities. Federal rules on the "essentially a copy" standard and shortage designations apply in California as in all states.

The FDA's "essentially a copy" standard prohibits compounding pharmacies from producing copies of commercially available drugs. In California, this standard has been interpreted strictly:

What it means: A compounded preparation that is identical — or nearly identical — to a commercially available drug (like Wegovy or Zepbound) may not be permissible.

The additive question: Adding B12, glycine, or another ingredient to a compounded GLP-1 creates a differentiated formulation. However, California regulators have scrutinized whether these additions provide genuine clinical differentiation or are merely cosmetic changes designed to circumvent the "essentially a copy" rule.

The 2025–2026 tightening: As branded semaglutide and tirzepatide have come off the FDA shortage list, California regulators have increased scrutiny of compounded GLP-1 preparations. Prescribers must document a genuine clinical rationale for the compounded formulation — not just the additive.

503A patient-specific compounding remains viable in California under the following conditions:

Patient-specific prescription: The prescription must be for a specific, identified patient — not for office stock or anticipatory compounding.

Clinical rationale: The prescriber must document why the patient needs a compounded preparation rather than the commercially available product. Acceptable rationales include:

• Patient cannot tolerate the commercially available formulation
• Patient requires a specific dose not available commercially
• Patient has a documented allergy to an excipient in the commercial product
• Cost/access barriers with documentation

Additive justification: If the formulation includes B12, glycine, or other additives, document the clinical rationale for each additive specific to the patient.

Pharmacy compliance: The compounding pharmacy must be licensed in California and compliant with California Board of Pharmacy rules.

California's AB-890 (effective January 1, 2023) allows nurse practitioners to practice independently after meeting specific requirements. For NPs prescribing compounded GLP-1s:

Standardized procedures: NPs practicing under standardized procedures (prior to full independent practice) must have physician oversight for prescribing compounded medications.

Independent practice NPs: NPs who have completed the transition to practice requirements and are practicing independently can prescribe compounded GLP-1s within their scope of practice.

Documentation: NPs must document their prescribing authority and the clinical basis for each compounded GLP-1 prescription.

503B outsourcing facilities face more restrictions on bulk GLP-1 compounding following the removal of semaglutide and tirzepatide from the FDA shortage list:

• 503B facilities cannot compound copies of commercially available drugs for office stock
• The removal of GLP-1s from the shortage list significantly limits 503B bulk GLP-1 compounding
• 503B facilities can still compound GLP-1 preparations that are genuinely differentiated from commercial products

1. Document clinical rationale for every compounded GLP-1 prescription — not just the additive, but why the patient needs a compounded preparation
2. Verify pharmacy licensure — ensure your compounding pharmacy is licensed in California
3. Review your prescribing authority — NPs should confirm their practice status under AB-890
4. Stay current — California regulations are evolving; subscribe to Board of Pharmacy updates
5. Partner with compliant suppliers — work with pharmacies that track California-specific rules

MedClinic Partners works with California-licensed compounding pharmacies and monitors California regulatory developments in real time.

Contact us with California compliance questions →

This content is for informational purposes only and does not constitute legal advice. California compounding regulations are subject to change. Consult with qualified legal counsel regarding your specific obligations.